[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619816":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":36,"locations":42,"responsibleParty":115,"collaborators":28,"id":117,"slug":28,"hasResults":118,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":28,"eligibilityCriteria":122,"healthyVolunteers":118,"sex":123,"minAge":124,"maxAge":28,"enrollmentInfo":125,"targetDuration":28,"studyType":128,"phases":129,"briefSummary":131,"conditions":132,"keywords":143,"overallStatus":45,"whyStopped":28,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":160},{"fullName":5,"class":6},"Revolution Medicines, Inc.","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm A: RMC-5127 Monotherapy","EXPERIMENTAL","Dose Escalation and Dose Expansion",[13],"Drug: RMC-5127",{"label":15,"type":10,"description":11,"interventionNames":16},"Arm B: RMC-5127 + Daraxonrasib Combination",[13,17],"Drug: daraxonrasib",{"label":19,"type":10,"description":11,"interventionNames":20},"Arm C: RMC-5127 + Cetuximab Combination",[13,21],"Drug: cetuximab",[23,29,32],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","RMC-5127","oral tablets",[9,15,19],null,{"type":24,"name":30,"description":26,"armGroupLabels":31,"otherNames":28},"daraxonrasib",[15],{"type":24,"name":33,"description":34,"armGroupLabels":35,"otherNames":28},"cetuximab","IV infusion",[19],[37],{"name":38,"role":39,"phone":40,"phoneExt":28,"email":41},"Revolution Medicines Study Director","CONTACT","1-844-2-REVMED","medinfo@revmed.com",[43,61,76,90,100],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"START Midwest","RECRUITING","Grand Rapids","Michigan","49546","United States",{"type":51,"coordinates":52},"Point",[53,54],-85.66809,42.96336,{"lat":54,"lon":53},[57],{"name":28,"role":39,"phone":58,"phoneExt":59,"email":60},"616-954-5554","ext. 4","hopeteam@startresearch.com",{"facility":62,"status":45,"city":63,"state":64,"zip":65,"country":49,"cosmosGeoPoint":66,"geoPoint":70,"contacts":71},"NEXT - Dallas","Dallas","Texas","75039",{"type":51,"coordinates":67},[68,69],-96.80667,32.78306,{"lat":69,"lon":68},[72],{"name":73,"role":39,"phone":74,"phoneExt":28,"email":75},"NEXT TXReferrels","972-893-8800","NXT_TXReferrals@nextoncology.com",{"facility":77,"status":45,"city":78,"state":64,"zip":79,"country":49,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"NEXT","San Antonio","78229",{"type":51,"coordinates":81},[82,83],-98.49363,29.42412,{"lat":83,"lon":82},[86],{"name":87,"role":39,"phone":88,"phoneExt":28,"email":89},"Jordan Georg","210-580-9521","jgeorg@nextoncology.com",{"facility":91,"status":45,"city":78,"state":64,"zip":79,"country":49,"cosmosGeoPoint":92,"geoPoint":94,"contacts":95},"START - San Antonio",{"type":51,"coordinates":93},[82,83],{"lat":83,"lon":82},[96],{"name":97,"role":39,"phone":98,"phoneExt":28,"email":99},"Isabel Jimenez","210-593-5265","isabel.jimenez@startresearch.com",{"facility":101,"status":45,"city":102,"state":103,"zip":104,"country":49,"cosmosGeoPoint":105,"geoPoint":109,"contacts":110},"NEXT - Virginia","Fairfax","Virginia","22031",{"type":51,"coordinates":106},[107,108],-77.30637,38.84622,{"lat":108,"lon":107},[111],{"name":112,"role":39,"phone":113,"phoneExt":28,"email":114},"Paolo Umayam","703-783-4546","pumayam@nextoncology.com",{"type":116,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100619816",false,"NCT07349537","Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors","Phase 1\u002F1b, Multicenter, Open-Label, Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors","Inclusion Criteria:\n\n* At least 18 years old and has provided informed consent.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Pathologically documented, locally advanced or metastatic KRAS G12V-mutated solid tumor malignancy.\n* Received and progressed or been intolerant to prior standard therapy (including targeted therapy) appropriate for tumor type and stage.\n* Measurable per RECIST v1.1\n* Adequate organ function (bone marrow, liver, kidney, coagulation).\n* Able to take oral medications.\n\nExclusion Criteria:\n\n* Primary central nervous system (CNS) tumors\n* Prior therapy with KRAS G12V inhibitor or direct RAS-targeted therapy (eg. degraders and\u002For inhibitors).\n* Any conditions that may affect the ability to take or absorb study drug.\n* Major surgery within 28 days prior to receiving study drug(s).\n* Patient is unable or unwilling to comply with protocol-required study visits or procedures.","ALL","18 Years",{"count":126,"type":127},574,"ESTIMATED","INTERVENTIONAL",[130],"PHASE1","The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or cetuximab in adults with KRAS G12V-mutant solid tumors.",[133,134,135,136,137,138,139,140,141,142],"Non-small Cell Lung Cancer (NSCLC)","Colorectal Cancer (CRC)","Pancreatic Adenocarcinoma","Pancreatic Ductal Adenocarcinoma (PDAC)","PDAC","CRC","NSCLC","Pancreatic Cancer","Lung Cancer (NSCLC)","Advanced Solid Tumors",[142,140,144,137,145,138,146,147,139,148,149,150],"Pancreatic Ductal Adenocarcinoma","Colorectal Cancer","Lung Cancer","Non-small Cell Lung Cancer","RAS","KRAS","RAS Mutation","2026-05-28",{"date":153,"type":154},"2026-06-01","ACTUAL",{"date":156,"type":154},"2026-01-08",{"date":158,"type":127},"2028-10",{"name":5,"class":6},5]